Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy Subjects

Wyeth is now a wholly owned subsidiary of Pfizer72 enrolled

Overview

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of single doses of HKI-357 administered to healthy subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Single-dose capsule

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Eligibility Criteria: * Healthy adult men or women of nonchildbearing potential, aged 18-50.

Safety, tolerability, PK

Time frame: 5 days

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.